Lexeo Therapeutics
7
2
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Clinical Course Of Disease In Participants With FA-CM
Role: lead
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Role: lead
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Role: lead
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
Role: lead
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
Role: lead
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
Role: lead
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Role: lead
All 7 trials loaded